MedicX Fund

LN: MXF

Market Cap£427m

Last Close 96.4p

MedicX Fund is a specialist REIT, listed on the premium segment of the LSE, investing in primary healthcare infrastructure in the UK and the Republic of Ireland.

More MedicX Fund content >

Investment summary

MedicX will report its results for the year ended 30 September 2018 in December. H218 included a significant portfolio acquisition and an important restructuring of some long-term debt facilities, increasing the company’s borrowing flexibility and extending its facilities at a lower marginal cost. NAV total return during Q3 was a strong 3.4%, following 8.0% in H118, while the pipeline of identified investment opportunities in the UK and the Republic of Ireland remained strong. The shares offer an attractive prospective yield of 4.8%, with full dividend cover, and currently trade at a small discount to NAV.

Y/E Sep
Revenue (£m)
EBITDA (£m)
PBT (£m)
EPS (fd) (p)
P/E (x)
P/CF (x)
2017A 35.9 N/A 33.3 3.6 26.8 N/A
2018A 39.1 N/A 49.1 3.9 24.7 N/A
2019E N/A N/A N/A N/A N/A N/A
2020E N/A N/A N/A N/A N/A N/A
Industry outlook

Healthcare planning, with broad political support, suggests strong underlying demand for modern healthcare properties in both the UK and the RoI. In addition to providing investment opportunities, this seems likely to support rental growth.

Last updated on 13/03/2019
Content on MedicX Fund
MedicX Fund (MXF); reports EPRA EPS increases of 11.4% from 3.5p to 3.9p
Financials | Edison Sparks | 11 December 2018
MedicX Fund – Quality portfolio, performing well
Financials | research Update | 6 November 2018
MedicX Fund – Signs of rental growth
Financials | research Update | 14 August 2018
View more
Sector
Financials
Access more Financials content
Share price graph
Price performance
%
1m
3m
12m
Actual 8.1 20.8 17.0
Relative* 8.3 15.4 17.6
52-week high/low 96.4p/73.2p
*% relative to local index
Key management
David Staples Chairman
Mike Adams CEO
Alan Pennell Financial Controller
Company website

You may also be interested in…